The following is a summary of “Steroid-resistant nephrotic syndrome due to renal-limited thrombotic microangiopathy and ...

Vertex Pharmaceuticals Incorporated today announced management participation in three upcoming investor conferences. Stuart Arbuckle, Executive Vice President and Chief Operating Officer, and David ...

Genentech has shared positive data from the Phase III REGENCY trial with regulators in the US and EU. Roche’s subsidiary ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...

The chronic kidney disease drug development landscape is evolving at an unprecedented pace, driven by breakthrough approvals, billion-dollar mergers and acquisitions, and increasing regulatory support ...

subsequently renamed the hepatitis B surface antigen (HBsAg), Combes and coworkers first described the occurrence of membranous nephropathy (MN) due to glomerular deposition of Australian antigen ...

Valeo Financial Advisors LLC bought a new stake in argenx SE (NASDAQ:ARGX – Free Report) during the 4th quarter, according to ...

which along with PNH and IgAN include atypical haemolytic uraemic syndrome (aHUS), C3 glomerulopathy (C3G), and idiopathic membranous nephropathy (IMN). IgAN is a key focus for Novartis ...

Reflecting these positive developments, Goldman Sachs has raised its 12-month target price for Everest Medicines to HK$48.32, nearly doubling from the previous HK$24.50. The upgrade factors in ...

Specifically, this antibody has been used to treat membranous nephropathy, cryoglobulinemic glomerulonephritis, systemic lupus erythematosus (SLE) and ANTINEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA ...